Abstract
The natural product combretastatin A-4 (CA4 )
is a potent anti-cancer agent known for its antimitotic and antiangiogenic properties.
The basic structure of CA4 has inspired
the design and synthesis of a variety of medicinally active analogues
that take advantage of the relatively simple stilbenoid architecture
of the molecule. Here, we examine recent advances in the synthesis
of various CA4 -based analogues. A significant
focus is placed on the modifications to the bridging alkene moiety
of the stilbene scaffold for conformationally restricting the structure
in a bioactive form. An effort is also made to discuss promising
ring modifications and replacements, including the incorporation
of indazole and oxindole rings, as well as the design and synthesis
of amino-substituted analogues.
1 Introduction
2 New Approaches for the Synthesis of CA4
3 Synthetic Approaches for the Preparation of CA4 Analogues
3.1 Modification of the Bridging Moiety
3.2 Modification of the Bridging Moiety via Heterocyclic Functionalities
3.3 Macrocyclic Rings Affording Conformational Restriction to
Combretastatin Analogues
4 Amine Substituents on Aryl Rings of Combretastatin Analogues
5 Conclusions
Key words
natural products - drugs - combretastatin - inhibitors - antitumor agents - medicinal
chemistry
References
1a
Watt JM.
Breyer-Brandwijk MG. In The Medicinal and Poisonous Plants of Southern
and Eastern Africa
2nd ed.:
E. and S. Livingstone;
London:
1962.
1b
Gurib FA.
Brendler T. In Medicinal
and Aromatic Plants of Indian Ocean Islands: Madagascar, Comoros,
Seychelles and Mascarenes
Medpharm Scientific Publishers;
Stuttgart:
2004.
2
Pettit GR.
Cragg GM.
Herald DL.
Schmidt JM.
Lobovanijaya P.
Can. J. Chem.
1982,
60:
1374
3
Pinney KG.
Jelinek C.
Edvardsen K.
Chaplin DJ.
Pettit GR. In Anticancer Agents
from Natural Products
Cragg GM.
Kingston DGI.
Newman DJ.
CRC/Taylor
and Francis;
Boca Raton:
2005.
p.23
4a
Cushman M.
Nagarathnam D.
Gopal D.
Chakraborty AK.
Lin CM.
Hamel E.
J.
Med. Chem.
1991,
34:
2579
4b
Sackett DL.
Pharm. Ther.
1993,
59:
163
4c
Hamel E.
Med.
Res. Rev.
1996,
16:
207
4d
Cirla A.
Mann J.
Nat. Prod. Rep.
2003,
20:
558
4e
Thorpe PE.
Clin. Cancer Res.
2004,
10:
415
4f
Li Q.
Sham HL.
Exp. Opin. Ther. Pat.
2002,
12:
1663
4g
Nam NH.
Curr.
Med. Chem.
2003,
10:
1697
4h
Pettit GR.
Lippert JW.
Herald DL.
Hamel E.
Pettit RK.
J. Nat. Prod.
2000,
63:
969
4i
Ohsumi K.
Nakagawa R.
Fukuda Y.
Hatanaka T.
Morinaga Y.
Nihei Y.
Ohishi K.
Suga Y.
Akiyama Y.
Tsuji T.
J. Med. Chem.
1998,
41:
3022
4j
Tron GC.
Pirali T.
Sorba G.
Pagliai F.
Busacca S.
Genazzani AA.
J. Med. Chem.
2006,
49:
3033
5
Lin CM.
Singh SB.
Chu PS.
Dempcy RO.
Schmidt JM.
Pettit GR.
Hamel E.
Mol. Pharmacol.
1988,
34:
200
6a
Grosios K.
Holwell SE.
McGown AT.
Pettit GR.
Bibby MC.
Br.
J. Cancer
1999,
81:
1318
6b
Horsman MR.
Murata R.
Breidahl T.
Nielsen FU.
Maxwell RJ.
Stodkiled-Jorgensen H.
Overgaard J.
Adv. Exp. Med. Biol.
2000,
476:
311
6c
Siemann DW.
Mercer E.
Lepler S.
Rojiani AM.
Int.
J. Cancer
2002,
99:
1
6d
Galbraith SM.
Maxwell RJ.
Lodge MA.
Tozer GM.
Wilson J.
Taylor NJ.
Stirling JJ.
Sena L.
Padhani AR.
Rustin GJ.
J. Clin. Oncol.
2003,
21:
2831
For antivascular activity of CA4 at
low concentrations, see:
6e
Tozer GM.
Kanthou C.
Parkins CS.
Hill SA.
Int. J.
Exp. Pathol.
2002,
83:
21
For examples of vascular-targeting tubulin binding compounds
in prodrug form, see:
6f
Hadimani MB.
Kessler RJ.
Kautz JA.
Ghatak A.
Shirali AR.
O’Dell H.
Garner CM.
Pinney KG.
Acta Crystallogr., Sect. C: Cryst. Struct.
Commun.
2002,
58:
330
6g
Siemann DW.
Rojiani AM.
Int.
J. Radiat. Oncol. Biol. Phys.
2002,
54:
1512
6h
Chaplin DJ.
Hill SA.
Int. J.
Radiat. Oncol. Biol. Phys.
2002,
54:
1491
6i
Thorpe PE.
Chaplin DJ.
Blakeley DC.
Cancer Res.
2003,
63:
1144
For a review on the current status of CA4P, see:
6j
Siemann DW.
Chaplin DJ.
Walicke PA.
Expert Opin. Investig. Drugs
2009,
18:
189
7a
Rustin GJS.
Galbraith SM.
Anderson H.
Stratford M.
Folkes LK.
Sena L.
Gumbrell L.
Price PM.
J. Clin. Oncol.
2003,
21:
2815
7b
Dowlati A.
Robertson K.
Cooney M.
Petros WP.
Stratford M.
Jesberger J.
Rafie N.
Overmoyer B.
Makkar V.
Stambler B.
Taylor A.
Waas J.
Lewin JS.
McCrae KR.
Remick SC.
Cancer Res.
2002,
62:
3408
8
Lee JC.
Harrison D.
Timasheff SN.
J.
Biol. Chem.
1975,
24:
9276
9
Dustin P.
Microtubules
2nd ed.:
Springer-Verlag;
Berlin:
1984.
10
Jordan MA.
Wilson L.
Nat. Rev. Cancer
2004,
4:
253
11a
Hamel E.
Pharm. Ther.
1992,
55:
31
11b
Shih C.
Teicher BA.
Curr. Pharm. Des.
2001,
7:
1259
11c
Gupta S.
Bhattacharya B.
Mol. Cell. Biochem.
2003,
253:
41
12
Atalay C.
Deliloglu GI.
Irkkan C.
Gunduz U.
Tumour Biol.
2006,
27:
309
13
Chaudhary A.
Pandeya SN.
Kumar P.
Sharma PP.
Gupta S.
Soni N.
Verma KK.
Bhardwaj G.
Mini Rev. Med. Chem.
2007,
7:
1186 ; and references therein
For the synthesis of (-)-combretastatin,
see:
14a
Pettit GR.
Singh SB.
Cragg GM.
J. Org. Chem.
1985,
50:
3404
For the synthesis of combretastatin-A1 and combretastatin-B1,
see:
14b
Pettit GR.
Singh SB.
Niven ML.
Hamel E.
Schmidt JM.
J. Nat. Prod.
1987,
50:
119
For the synthesis of combretastatin-A2, combretastatin-A3
and combretastatin-B2, see:
14c
Pettit GR.
Singh SB.
Can.
J. Chem.
1987,
65:
2390
For a previous report on the synthesis of (±)-combretastatin,
see:
14d
Annapurna GS.
Deshpande VH.
Synth.
Commun.
1983,
13:
1075
15
Pettit GR.
Singh SB.
Boyd MR.
Hamel E.
Pettit RK.
Schmidt JM.
Hogan F.
J.
Med. Chem.
1995,
38:
1666
16
Harrowven DC.
Guy IL.
Howell M.
Packam G.
Synlett
2006,
2977
17a
Dunne EC.
Coyne J.
Crowley PB.
Gilheany DG.
Tetrahedron Lett.
2002,
43:
2449
17b See also: Hwang
J.-J.
Lin R.-L.
Shieh R.-L.
Jwo J.-J.
J. Mol.
Catal. A: Chem.
1999,
142:
125
17c
Sinhababu AK.
Borchardt RT.
J.
Org. Chem.
1983,
48:
2356
18
Robinson JE.
Taylor RJK.
Chem. Commun.
2007,
1617
19
Chan T.-L.
Fong S.
Li Y.
Man T.-O.
Poon C.-D.
J. Chem.
Soc., Chem. Commun.
1994,
1771
20
Yang G.
Franck RW.
Byun H.-S.
Bittman R.
Samadder P.
Arthur G.
Org. Lett.
1999,
1:
2149
21
Meyers CY.
Malte AM.
Matthews WS.
J. Am. Chem. Soc.
1969,
91:
7510
22
Giraud A.
Provot O.
Hamze A.
Brion J.-D.
Alami M.
Tetrahedron
Lett.
2008,
49:
1107
23a
Hamze A.
Provot O.
Brion J.-D.
Alami M.
Synthesis
2007,
2025
23b
Hamze A.
Provot O.
Alami M.
Brion
J.-D.
Org. Lett.
2005,
7:
5625
24a
Lindlar H.
Helv. Chim. Acta
1952,
35:
446
24b
Lindlar H.
Dubuis R.
Org. Synth.
1973,
5:
880
25a
Bujard M.
Ferri F.
Alami M.
Tetrahedron Lett.
1998,
39:
4243
25b
Liron F.
Le Garrec P.
Alami M.
Synlett
1999,
246
25c
Alami M.
Liron F.
Gervais M.
Peyrat
J.-F.
Brion J.-D.
Angew.
Chem. Int. Ed.
2002,
41:
1578
25d
Liron F.
Gervais M.
Peyrat J.-F.
Alami M.
Brion
J.-D.
Tetrahedron
Lett.
2003,
44:
2789
25e
Hamze A.
Provot O.
Brion J.-D.
Alami M.
J. Org. Chem.
2007,
72:
3868
26
Zou Y.
Xiao C.-F.
Zhong R.-Q.
Wei W.
Huang W.-M.
He S.-J.
J.
Chem. Res.
2008,
354
27
Camacho-Davila AA.
Synth. Commun.
2008,
3823
28
Pettit GR.
Cragg GM.
Singh SB.
J.
Nat. Prod.
1987,
56:
386
29
Ravelli RBG.
Gigant B.
Curmi PA.
Jourdain I.
Lachkar S.
Sobel A.
Knossow M.
Nature
2004,
428:
198
For examples of bridge modified
tubulin polymerization inhibitors, see:
30a Synthesis of phenstatin: Pettit GR.
Toki B.
Herald DL.
Verdier-Pinard P.
Boyd MR.
Hamel E.
Pettit RK.
J. Med. Chem.
1998,
41:
1688
30b Synthesis of hydroxy-phenstatin: Pettit GR.
Grealish MP.
Herald DL.
Boyd MR.
Hamel E.
Pettit RK.
J. Med. Chem.
2000,
43:
2731
31
Gurjar MK.
Wakharkar RD.
Singh AT.
Jaggi M.
Borate HB.
Shinde PD.
Verma R.
Rajendran P.
Dutt S.
Singh G.
Sanna VK.
Singh MK.
Srivastava SK.
Mahajan VA.
Jadhav VH.
Dutta K.
Krishnan K.
Chaudhary A.
Agarwal SK.
Mukherjee R.
Burman AC.
J. Med. Chem.
2007,
50:
1744
32 Gurjar MK, Wakharkar RD, Desiraju GR, Nangia A, Yadav JS, Burman AC, Mukherjee R, Borate HB, Chandrasekhar S, Jaggi M, Singh AT, Kapoor KK, Sarkhel S, and Sairam KVVM. inventors; US
Pat. Appl. Publ. US 2003229146.
33
Trost BM.
Pinkerton AB.
J. Org. Chem.
2001,
66:
7714
34
Kerr DJ.
Hamel E.
Jung MK.
Flynn BL.
Bioorg. Med. Chem.
2007,
15:
3290
35
Kerr DJ.
Metje C.
Flynn BL.
Chem.
Commun.
2003,
1380
36
Sriram M.
Hall JJ.
Grohman NC.
Strecker TE.
Wooton T.
Franken A.
Trawick ML.
Pinney KG.
Bioorg.
Med. Chem.
2008,
16:
8161
37
Hu L.
Li Z.-R.
Li Y.
Qu J.
Ling Y.-H.
Jiang J.-D.
Boykin DW.
J. Med. Chem.
2006,
49:
6273
38
Mitsumori S.
Tsuri T.
Honma T.
Hiramatsu Y.
Okada T.
Hashizume H.
Inagaki M.
Arimura A.
Yasui K.
Asanuma F.
Kishino J.
Ohtani M.
J. Med. Chem.
2003,
46:
2436
39
Mousset C.
Giraud A.
Provot O.
Hamze A.
Bignon J.
Liu J.-M.
Thoret S.
Dubois J.
Brion J.-D.
Alami M.
Bioorg. Med. Chem. Lett.
2008,
18:
3266
40
Giraud A.
Provot O.
Peyrat J.-F.
Alami M.
Brion J.-D.
Tetrahedron
2006,
62:
7667
41
Sun L.
Vasilevich NI.
Fuselier JA.
Hocart SJ.
Coy DH.
Bioorg.
Med. Chem. Lett.
2004,
14:
2041
42
Kaffy J.
Monneret C.
Mailliet P.
Commercon A.
Pontinkis R.
Tetrahedron
Lett.
2004,
45:
3359
43
Wang L.
Woods KW.
Li Q.
Barr KJ.
McCroskey RW.
Hannick SM.
Gherke L.
Credo RB.
Hui Y.-H.
Marsh K.
Warner RJ.
Lee Y.
Zielenski-Mozng N.
Frost D.
Rosenberg S.-H.
Sham HL.
J.
Med. Chem.
2002,
45:
1697
44
LeBlanc R.
Dickson J.
Brown T.
Stewart M.
Pati H.
VanDerveer D.
Arman H.
Harris J.
Pennington W.
Holt H.
Lee M.
Bioorg. Med. Chem.
2005,
13:
6025
45
Flynn BL.
Flynn GP.
Hamel E.
Jung MK.
Bioorg. Med. Chem. Lett.
2001,
11:
2341
46
Pinney KG.
Bounds AD.
Dingeman KM.
Mocharla VP.
Pettit GR.
Bai R.
Hamel E.
Bioorg. Med. Chem. Lett.
1999,
9:
1081
47
Kim Y.
Nam N.-H.
You Y.-J.
Ahn B.-Z.
Bioorg. Med. Chem. Lett.
2002,
12:
719
48
Zhang Q.
Peng Y.
Wang XI.
Keenan SM.
Arora S.
Welsh WJ.
J. Med. Chem.
2007,
50:
749
49
Curphey TJ.
J.
Org. Chem.
2002,
67:
6467
50 The conformation from the X-ray crystal
structure was utilized in molecular dynamics simulations by docking
it into the colchicines binding site of tubulin by Zhang et al.48
51
Nguyen TL.
McGrath C.
Hermone AR.
Burnett JC.
Zaharevitz DW.
Day BW.
Wipf P.
Hamel E.
Gussio RA.
J. Med. Chem.
2005,
48:
6107
52
Odlo K.
Hentzen J.
Chabert JFD.
Ducki S.
Gani OABSM.
Sylte I.
Skrede M.
Florenes VA.
Hansen TV.
Bioorg. Med. Chem.
2008,
16:
4829
53
Colvin EW.
Hamill BJ.
J. Chem. Soc., Chem.
Commun.
1973,
151
54
Huisgen R.
Szeimies G.
Mobius L.
Chem.
Ber.
1967,
100:
2494
55
Johnson M.
Younglove B.
Lee L.
LeBlanc R.
Holt H.
Hills P.
Mackay H.
Brown T.
Mooberry SL.
Lee M.
Bioorg. Med. Chem. Lett.
2007,
17:
5897
56
Ducki S.
Forrest R.
Hadfield JH.
Kendall A.
Lawrence NJ.
McGown AT.
Rennison D.
Bioorg.
Med. Chem. Lett.
1998,
8:
1051
57a
Sun L.
Tran N.
Tang F.
App H.
Hirth P.
McMahon G.
Tang C.
J.
Med. Chem.
1998,
41:
2588
57b
Sun L.
Tran N.
Liang C.
Tang F.
Rice A.
Schreck R.
Waltz K.
Shawver LK.
McMahon G.
Tang C.
J. Med.
Chem.
1999,
42:
5120
58
Pandit B.
Sun Y.
Chen P.
Sackett DL.
Hu Z.
Rich W.
Li C.
Lewis A.
Schaefer K.
Li P.-K.
Bioorg.
Med. Chem.
2006,
14:
6492
59
Li P.-K.
Xiao Z.
Hu Z.
Pandit B.
Sun Y.
Sackett DL.
Werbovetz K.
Lewis A.
Johnsamuel J.
Bioorg.
Med. Chem. Lett.
2005,
15:
5382
60
Quallich G.
Morrissey P.
Synthesis
1993,
51
61
Arthuis M.
Pontikis R.
Florent J.-C.
Tetrahedron
Lett.
2007,
48:
6397
62
Kaffy J.
Pontikis R.
Florent J.-C.
Monneret C.
Org. Biomol. Chem.
2005,
5:
2657
63a
Cheung WS.
Patch RJ.
Player MR.
J.
Org. Chem.
2005,
70:
3741
63b
Yanada R.
Obika S.
Inokuma T.
Yanada K.
Yamashita M.
Ohta S.
Takemoto Y.
J.
Org. Chem.
2005,
70:
6972
64
Couty S.
Liégault B.
Meyer C.
Cossy J.
Org. Lett.
2004,
6:
2511
65a
Oh CH.
Lim YM.
Tetrahedron
Lett.
2003,
44:
267
65b
Min S.-H.
Pang S.-J.
Cho C.-G.
Tetrahedron
Lett.
2003,
44:
4439
66
Burns B.
Grigg R.
Sridharan V.
Stevenson P.
Sukirthalingam S.
Worakun T.
Tetrahedron Lett.
1989,
30:
1135
67
Yanada R.
Obika S.
Kobayashi Y.
Inokuma T.
Oyama M.
Yanada K.
Takemoto Y.
Adv.
Synth. Catal.
2005,
347:
1632
68
Brunton SA.
Jones K.
J. Chem. Soc., Perkin Trans.
1
2000,
763
69
Duan J.-X.
Cai X.
Meng F.
Lan L.
Hart C.
Matteucci M.
J. Med. Chem.
2007,
50:
1001
70
Provot O.
Giraud A.
Peyrat J.
Alami M.
Brion J.
Tetrahedron
Lett.
2005,
49:
8547
71
Idiya GF.
Nataliya AZ.
Tetrahedron Lett.
2005,
29:
5453
72
Wu M.
Sun Q.
Yang C.
Chen D.
Ding J.
Chen Y.
Lin L.
Xie Y.
Bioorg. Med.
Chem. Lett.
2007,
17:
869
73
Napolitano E.
Ramacciotti A.
Gazz. Chim. Ital.
1989,
119:
19
74
Tong YG.
Zhang XW.
Geng MY.
Yue JM.
Xin XL.
Fang T.
Xu S.
Tong LJ.
Li MH.
Zhang C.
Li WH.
Lin LP.
Ding J.
Mol.
Pharmacol.
2006,
69:
1226
75
Lee L.
Davis R.
Vanderham J.
Hills P.
Mackay H.
Brown T.
Mooberry SL.
Lee M.
Eur.
J. Med. Chem.
2008,
43:
2011
76 For the synthesis and a limited
cytotoxicity study of chalcones, see: Dickson J.
Flores L.
Stewart M.
Holt HL.
LeBlanc R.
Lee M.
J. Chem. Educ.
2006,
83:
934
77
Rappl C.
Barbier P.
Bourgarel-Rey V.
Gregoire C.
Gilli R.
Carre M.
Combes S.
Finet J.-P.
Peyrot V.
Biochemistry
2006,
45:
9210
78
Bailly C.
Bal C.
Barbier P.
Combes S.
Finet J.-P.
Hildebrand M.-P.
Peyrot V.
Wattez N.
J. Med. Chem.
2003,
46:
5437
79
Combes S.
Finet J.-P.
Siri D.
J.
Chem. Soc., Perkin Trans. 1
2002,
38
80a
Ishiyama T.
Abe S.
Miyaura N.
Suzuki A.
Chem. Lett.
1992,
691
80b
Miyaura N.
Ishiyama T.
Sasaki H.
Ishikawa M.
Satoh M.
Suzuki A.
J. Am. Chem. Soc.
1989,
111:
314
80c
Miyaura N.
Yanagi T.
Suzuki A.
Synth. Commun.
1981,
11:
513
80d
Miyaura N.
Yamada K.
Suzuki A.
Tetrahedron
Lett.
1979,
36:
3437
80e
Miyaura N.
Suzuki A.
Chem. Rev.
1995,
95:
2457
80f
Miyaura N.
Top.
Curr. Chem.
2002,
219:
11
80g
Suzuki A.
J. Organomet.
Chem.
1999,
576:
147
80h
Hassan J.
Sevignon M.
Gozzi C.
Schulz E.
Lemaire M.
Chem. Rev.
2002,
102:
1359
81a
Walker SD.
Barder TE.
Martinelli JR.
Buchwald SL.
Angew. Chem. Int. Ed.
2004,
43:
1871
81b
Zhou J.
Fu GC.
J. Am. Chem. Soc.
2004,
126:
1340
81c
Brenstrum T.
Gerristma DA.
Adjabeng GM.
Frampton CS.
Britten J.
Rabertson AJ.
McNulty J.
Capretta A.
J. Org.
Chem.
2004,
69:
7635
81d
Arensten K.
Caddick S.
Cloke FGN.
Herring AP.
Hitchcock PB.
Tetrahedron Lett.
2004,
45:
3511
81e
Gstottmayr CWK.
Bohm VPW.
Herdtweck E.
Grosche M.
Herrmann WA.
Angew. Chem. Int.
Ed.
2002,
41:
1363
81f
Navarro O.
Kaur H.
Poppet B.
Mahjoor P.
Nolan SP.
J.
Org. Chem.
2004,
69:
3173
81g
Singh R.
Viciu MS.
Kramareva N.
Navarro O.
Nolan SP.
Org.
Lett.
2005,
7:
1829
82a
Boland GM.
Donnelly DMX.
Finet J.-P.
Rea MD.
J. Chem. Soc., Perkin Trans. 1
1996,
2591
82b
Donnelly DMX.
Finet J.-P.
Guiry PJ.
Rea MD.
Synth.
Commun.
1999,
29:
2719
83
Ganina OG.
Daras E.
Bourgarel-Rey V.
Peyrot V.
Andresyuk AN.
Finet J.-P.
Federov AY.
Beletskaya I.
Combes S.
Bioorg.
Med. Chem.
2008,
16:
8806
84a
Pettit GR.
Singh SB.
Niven ML.
J.
Am. Chem. Soc.
1988,
110:
8539
84b
Singh SB.
Pettit GR.
J.
Org. Chem.
1990,
55:
2797
85
Mateo C.
Lopez V.
Medarde M.
Pelaez R.
Chem. Eur. J.
2007,
13:
7246
86
Maya ABS.
Pérez-Melero C.
Mateo C.
Alonso D.
Fernández JL.
Gajate C.
Mollinedo F.
Peláez R.
Caballero E.
Medarde M.
J. Med.
Chem.
2005,
48:
556
87a
Mitsunobu O.
Synthesis
1981,
1
87b
Hughes DL.
Org. React.
1992,
42:
335
87c
Hughes DL.
Org. Prep. Proced. Int.
1996,
28:
127
88
McMurry JE.
Chem.
Rev.
1989,
89:
1513
89
Mateo C.
Pérez-Melero C.
Peláez R.
Medarde M.
J. Org.
Chem.
2005,
70:
6544
90
Mateo C.
Alvarez R.
Perez-Melero C.
Pelaez R.
Medarde M.
Bioorg.
Med. Chem. Lett.
2007,
17:
6316
91
Pettit GR.
Rhodes MR.
Herald DL.
Hamel E.
Schmidt JM.
Pettit RK.
J.
Med. Chem.
2005,
48:
4087
92a
Monk KA.
Siles R.
Hadimani MB.
Mugabe BE.
Ackley JF.
Studerus SW.
Edvardsen K.
Trawick ML.
Garner CM.
Rhodes MR.
Pettit GR.
Pinney KG.
Bioorg.
Med. Chem.
2006,
14:
3231
For earlier reports on the synthesis of 3′-amino
combretastatin tubulin polymerization inhibitors, see:
92b Ref. 4i.
92c
Pinney KG.
Mejia MP.
Villalobos VM.
Rosenquist BE.
Pettit GR.
Verdier-Pinard P.
Hamel E.
Bioorg. Med. Chem.
2000,
8:
2417
93
Chang J.-Y.
Yang M.-F.
Chang C.-Y.
Chn C.-M.
Kuo C.-C.
Liou J.-P.
J. Med. Chem.
1996,
49:
6412
94
Siles R.
Ackley JF.
Hadimani MB.
Hall JJ.
Mugabe BE.
Guddneppanavar R.
Monk KA.
Chapuis J.-C.
Pettit GR.
Chaplin DJ.
Edvardsen K.
Trawick ML.
Garner CM.
Pinney KG.
J. Nat. Prod.
2008,
71:
313
95
Gal’bershtam MA.
Budarina ZN.
Zh.
Org. Khim.
1969,
5:
953
96
Simonsen JL.
Rau MG.
J. Chem. Soc., Dalton
Trans.
1917,
220:
236
97
Monk K.
Siles R.
Pinney KG.
Garner CM.
Tetrahedron Lett.
2003,
44:
3759
98 Chaplin DJ, Garner CM, Kane RR, Pinney KG, Prezioso JA, and Edvardsen K. inventors; United
States Patent US 6919324B2.